Research Analysts Set Expectations for F-star Therapeutics, Inc.’s Q2 2022 Earnings (NASDAQ:FSTX)

F-star Therapeutics, Inc. (NASDAQ:FSTXGet Rating) – Equities research analysts at Oppenheimer boosted their Q2 2022 earnings per share (EPS) estimates for F-star Therapeutics in a research report issued to clients and investors on Wednesday, May 11th. Oppenheimer analyst H. Singh now forecasts that the company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.66). Oppenheimer also issued estimates for F-star Therapeutics’ Q3 2022 earnings at ($0.59) EPS, Q4 2022 earnings at ($0.41) EPS, FY2022 earnings at ($2.04) EPS, FY2023 earnings at ($2.73) EPS, FY2024 earnings at ($2.50) EPS, FY2025 earnings at ($2.76) EPS and FY2026 earnings at ($0.36) EPS.

Other analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of F-star Therapeutics in a research note on Thursday, March 17th. Zacks Investment Research raised shares of F-star Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from, the stock has a consensus rating of “Buy” and an average target price of $25.21.

NASDAQ FSTX opened at $2.33 on Monday. The firm has a 50-day moving average of $3.19 and a 200-day moving average of $4.18. The company has a debt-to-equity ratio of 0.14, a quick ratio of 6.98 and a current ratio of 6.11. The stock has a market cap of $50.23 million, a PE ratio of -1.51 and a beta of 1.86. F-star Therapeutics has a 52-week low of $2.07 and a 52-week high of $9.71.

A number of large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in F-star Therapeutics in the 4th quarter valued at about $29,000. JPMorgan Chase & Co. bought a new position in F-star Therapeutics in the 4th quarter valued at about $42,000. Envestnet Asset Management Inc. bought a new position in F-star Therapeutics in the 1st quarter valued at about $48,000. Morgan Stanley increased its holdings in F-star Therapeutics by 65.0% in the 2nd quarter. Morgan Stanley now owns 7,868 shares of the company’s stock valued at $68,000 after buying an additional 3,100 shares during the period. Finally, Millennium Management LLC bought a new position in F-star Therapeutics in the 3rd quarter valued at about $114,000. 51.67% of the stock is currently owned by institutional investors and hedge funds.

About F-star Therapeutics (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Further Reading

Earnings History and Estimates for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with's FREE daily email newsletter.